Lee Suk-Young, Seo Hyo Jung, Kim Sungeun, Eo Jae Seon, Oh Sang Cheul
Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Department of Nuclear Medicine, Korea University College of Medicine, Seoul, Korea.
Asia Pac J Clin Oncol. 2018 Oct;14(5):e302-e309. doi: 10.1111/ajco.12833. Epub 2017 Dec 10.
To evaluate the prognostic role of interim analysis of 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) volumetric parameters in patients with recurrent or metastatic advanced gastric cancer (AGC) treated with fluoropyrimidine-based palliative chemotherapy.
Forty-four patients who underwent baseline and interim PET/CT scanning during palliative chemotherapy were analyzed retrospectively. Initial and change of metabolic parameters (MP) - metabolic tumor volume (MTV), tumor lesion glycolysis (TLG) and maximum and mean standardized uptake values (SUV) were measured with PET/CT. Metabolic change was measured by ∆MP (%) = (MP - MP )/MP × 100. Independent t-test was employed to compare values of initial, interim and change of metabolic parameters between each response group. Log-rank test was employed for univariate analysis, and multivariate analysis was performed using the Cox proportional hazards regression model to determine independently significant prognostic factors.
Reduced percentage values of maximum and mean SUV on interim PET/CT and initial values of volumetric parameters (MTV and TLG) were significant predicting factors to response to fluoropyrimidine-based palliative chemotherapy. The decreased percentage values of metabolic parameters as well as maximum and mean SUV with receiver operating characteristic (ROC) curve determined cut-off points were significant prognostic factors for overall survival and progression-free survival in univariate and multivariate analyses.
Measurement of metabolic decrease of volumetric parameters by interim PET/CT analysis is useful to determine the prognosis of patients with recurrent or metastatic AGC.
评估18F-氟脱氧葡萄糖(FDG)正电子发射断层扫描-计算机断层扫描(PET/CT)体积参数的中期分析在接受氟嘧啶类姑息化疗的复发或转移性晚期胃癌(AGC)患者中的预后作用。
回顾性分析44例在姑息化疗期间接受基线和中期PET/CT扫描的患者。用PET/CT测量代谢参数(MP)的初始值和变化值——代谢肿瘤体积(MTV)、肿瘤病灶糖酵解(TLG)以及最大和平均标准化摄取值(SUV)。代谢变化通过∆MP(%)=(MP - MP )/MP × 100来测量。采用独立样本t检验比较各反应组之间代谢参数的初始值、中期值和变化值。采用对数秩检验进行单因素分析,并使用Cox比例风险回归模型进行多因素分析,以确定独立的显著预后因素。
中期PET/CT上最大和平均SUV的降低百分比值以及体积参数(MTV和TLG)的初始值是对氟嘧啶类姑息化疗反应的显著预测因素。代谢参数以及最大和平均SUV的降低百分比值与通过受试者工作特征(ROC)曲线确定的截断点在单因素和多因素分析中都是总生存和无进展生存的显著预后因素。
通过中期PET/CT分析测量体积参数的代谢降低对确定复发或转移性AGC患者的预后有用。